Similar to the 2020 resolution, Novartis AG’s $25 million 2016 civil resolution While using the SEC worried inappropriate sponsorships of HCPs to conferences and poor payments to HCPs to collect “clinical information.” The fact that Novartis is now experiencing a substantially more substantial—and criminal—resolution for identical miscond